General
Preferred name
MECLOFENAMIC ACID
Synonyms
MECLOFENAMATE SODIUM ()
CL-583.NA SALT ()
Meclofenamic acid sodium ()
Meclomen ()
Meclonax ()
Movens ()
Meclofenamate ()
Meclofenamic acid sodium salt monohydrate ()
meclofenamic-acid ()
CB1 antagonist, Bayer ()
Meclofenamic acid (sodium) ()
Meclofenamate (sodium) ()
CI 583 ()
CL-583 ()
Meclodium ()
NSC-757088 ()
Meclofenamate sodium anhydrous ()
Sodium meclofenamate monohydrate ()
Meclofenamate sodium hydrate ()
Sodium meclofenamate ()
CI-583 ()
NSC-95309 ()
INF-4668 ()
INF 4668 ()
Meclofenamate (sodium salt) ()
P&D ID
PD009630
CAS
6385-02-0
644-62-2
67254-91-5
Tags
drug candidate
natural product
drug
available
Approved by
FDA
First approval
1980
Drug Status
approved
vet_approved
Drug indication
Joint pain
Arthritis
Obesity
Anti-Inflammatory
Ankylosing spondylitis
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Meclofenamic acid is a non-steroidal anti-inflammatory drug (NSAID). (GtoPdb)
DESCRIPTION Cyclooxygenase and 5-Lipoxygenase inhibitor (LOPAC library)
DESCRIPTION Meclofenamic Acid is a non-steroidal anti-inflammatory agent. It has antipyretic and antigranulation activities and is used as a drug used for muscular pain, joint, arthritis and dysmenorrhea. It is a member of the anthranilic acid derivatives class of NSAID drugs. It is also a COX inhibitor and inhibits prostaglandin biosynthesis. It was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site in animal studies. It was found to be an inhibitor of human leukocyte 5-lipoxygenase activity in vitro. It has been listed. (BOC Sciences Bioactive Compounds)
Cell lines
1
Organisms
2
Compound Sets
33
BOC Sciences Bioactive Compounds
meclofenamic-acid-cas-644-62-2-item-74329
Cayman Chemical Bioactives
70550
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1562610
CHEMBL509
ChEMBL Drugs
CHEMBL1562610
CHEMBL509
Concise Guide to Pharmacology 2019/20
7219
Concise Guide to Pharmacology 2021/22
7219
Concise Guide to Pharmacology 2023/24
7219
Drug Repurposing Hub
DrugBank
DB00939
DrugBank Approved Drugs
DB00939
DrugCentral
1650
DrugCentral Approved Drugs
1650
DrugMAP
DMNL98G
DM53JW0
DM05FXR
DrugMAP Approved Drugs
DMNL98G
DM05FXR
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101837
Guide to Pharmacology
7219
JUMP-Target 1 Compound Set
4037
Ki Database
Meclofenamate
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL876
CHEMBL509
MedChem Express Bioactive Compound Library
HY-B1320
NCATS Inxight Approved Drugs
48I5LU4ZWD
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
meclofenamate-sodium
TargetMol Bioactive Compound Library
T0260
The Spectrum Collection
ZINC Tool Compounds
ZINC000000001655
External IDs
74
Properties
(calculated by RDKit )
Molecular Weight
295.02
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
2
cLogP
4.74
TPSA
49.33
Fraction CSP3
0.07
Chiral centers
0.0
Largest ring
6.0
QED
0.86
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
cyclooxygenase inhibitor
Phospholipase inhibitor
COX inhibitor
cyclooxygenase inhibitor, prostanoid receptor antagonist
Target
Arachidonate 5-lipoxygenase
cyclooxygenase
COX-1
COX-2
ALOX5, CNR1, KCNQ2, KCNQ3, PTGS1, PTGS2
KCNQ2
Endogenous Metabolite
Gap Junction Protein
COX,FTO
Selectivity
COX / 5-Lipoxygenase
Pathway
Immunology/Inflammation
Neuroscience
cytoskeleton
Metabolic Enzyme/Protease
Indication
joint pain, muscle pain, rheumatoid arthritis, primary dysmenorrhea (PD)
Disease Area
rheumatology, neurology/psychiatry, endocrinology
Therapeutic Class
Analgesics
Solubility
Soluble in Chloroform (Slightly), Methanol (Slightly, Heated)
Source data